Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Change in Receivables: 2010-2025

Historic Change in Receivables for Arrowhead Pharmaceuticals (ARWR) over the last 13 years, with Sep 2025 value amounting to $47.1 million.

  • Arrowhead Pharmaceuticals' Change in Receivables was N/A to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.0 million, marking a year-over-year change of. This contributed to the annual value of $57.0 million for FY2025, which is N/A change from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Change in Receivables stood at $47.1 million for Q3 2025, which was up 530.36% from $7.5 million recorded in Q2 2025.
  • Arrowhead Pharmaceuticals' 5-year Change in Receivables high stood at $47.1 million for Q3 2025, and its period low was -$68.2 million during Q2 2023.
  • Its 3-year average for Change in Receivables is $2.5 million, with a median of $2.5 million in 2024.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Change in Receivables slumped by 9,960.00% in 2021 and then surged by 2,459.30% in 2023.
  • Arrowhead Pharmaceuticals' Change in Receivables (Quarterly) stood at -$10.1 million in 2021, then soared by 477.61% to $38.2 million in 2022, then tumbled by 206.40% to -$1.2 million in 2023, then reached $2.5 million in 2024, then reached $47.1 million in 2025.
  • Its Change in Receivables was $47.1 million in Q3 2025, compared to $7.5 million in Q2 2025 and -$135,000 in Q1 2025.